52 related articles for article (PubMed ID: 28947240)
21. PMCA2 silencing potentiates MDA-MB-231 breast cancer cell death initiated with the Bcl-2 inhibitor ABT-263.
Curry M; Roberts-Thomson SJ; Monteith GR
Biochem Biophys Res Commun; 2016 Sep; 478(4):1792-7. PubMed ID: 27613092
[TBL] [Abstract][Full Text] [Related]
22. Inhibitory effects of everolimus in combination with paclitaxel on adriamycin-resistant breast cancer cell line MDA-MB-231.
Xu T; Liu P; Li Q; Shi C; Wang X
Taiwan J Obstet Gynecol; 2020 Nov; 59(6):828-834. PubMed ID: 33218396
[TBL] [Abstract][Full Text] [Related]
23. Wogonin induces apoptosis and down-regulates survivin in human breast cancer MCF-7 cells by modulating PI3K-AKT pathway.
Huang KF; Zhang GD; Huang YQ; Diao Y
Int Immunopharmacol; 2012 Feb; 12(2):334-41. PubMed ID: 22182776
[TBL] [Abstract][Full Text] [Related]
24. Iron-free and iron-saturated bovine lactoferrin inhibit survivin expression and differentially modulate apoptosis in breast cancer.
Gibbons JA; Kanwar JR; Kanwar RK
BMC Cancer; 2015 May; 15():425. PubMed ID: 25998617
[TBL] [Abstract][Full Text] [Related]
25. Navitoclax enhances the efficacy of taxanes in non-small cell lung cancer models.
Tan N; Malek M; Zha J; Yue P; Kassees R; Berry L; Fairbrother WJ; Sampath D; Belmont LD
Clin Cancer Res; 2011 Mar; 17(6):1394-404. PubMed ID: 21220478
[TBL] [Abstract][Full Text] [Related]
26. Human breast cancer cells display different sensitivities to ABT-263 based on the level of survivin.
Lee EY; Gong EY; Shin JS; Moon JH; Shim HJ; Kim SM; Lee S; Jeong J; Gong JH; Kim MJ; Lee DH; Park YS; Shin J; Hong SW; Kim YS; Jin DH
Toxicol In Vitro; 2018 Feb; 46():229-236. PubMed ID: 28947240
[TBL] [Abstract][Full Text] [Related]
27. Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer.
Merino D; Lok SW; Visvader JE; Lindeman GJ
Oncogene; 2016 Apr; 35(15):1877-87. PubMed ID: 26257067
[TBL] [Abstract][Full Text] [Related]
28. Survivin as a preferential target for cancer therapy.
Mobahat M; Narendran A; Riabowol K
Int J Mol Sci; 2014 Feb; 15(2):2494-516. PubMed ID: 24531137
[TBL] [Abstract][Full Text] [Related]
29. Survivin as a prognostic/predictive marker and molecular target in cancer therapy.
Rödel F; Sprenger T; Kaina B; Liersch T; Rödel C; Fulda S; Hehlgans S
Curr Med Chem; 2012; 19(22):3679-88. PubMed ID: 22680927
[TBL] [Abstract][Full Text] [Related]
30. Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin.
Kelly RJ; Lopez-Chavez A; Citrin D; Janik JE; Morris JC
Mol Cancer; 2011 Apr; 10():35. PubMed ID: 21470426
[TBL] [Abstract][Full Text] [Related]
31. Clinical Review: Navitoclax as a Pro-Apoptotic and Anti-Fibrotic Agent.
Mohamad Anuar NN; Nor Hisam NS; Liew SL; Ugusman A
Front Pharmacol; 2020; 11():564108. PubMed ID: 33381025
[TBL] [Abstract][Full Text] [Related]
32. Nanoparticle-mediated inhibition of survivin to overcome drug resistance in cancer therapy.
Wang S; Xu Y; Chan HF; Kim HW; Wang Y; Leong KW; Chen M
J Control Release; 2016 Oct; 240():454-464. PubMed ID: 27091696
[TBL] [Abstract][Full Text] [Related]
33. Clinico-pathologic relevance of Survivin splice variant expression in cancer.
Necochea-Campion Rd; Chen CS; Mirshahidi S; Howard FD; Wall NR
Cancer Lett; 2013 Oct; 339(2):167-74. PubMed ID: 23791888
[TBL] [Abstract][Full Text] [Related]
34. Combination Therapy of Navitoclax with Chemotherapeutic Agents in Solid Tumors and Blood Cancer: A Review of Current Evidence.
Nor Hisam NS; Ugusman A; Rajab NF; Ahmad MF; Fenech M; Liew SL; Mohamad Anuar NN
Pharmaceutics; 2021 Aug; 13(9):. PubMed ID: 34575429
[TBL] [Abstract][Full Text] [Related]
35. Transcriptional regulation of the survivin gene.
Boidot R; Végran F; Lizard-Nacol S
Mol Biol Rep; 2014 Jan; 41(1):233-40. PubMed ID: 24197699
[TBL] [Abstract][Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
